EMPIRI is a translational precision oncology company based in Houston, Texas. We developed E-slice, an ex vivo platform that keeps fresh human tumor tissue intact, preserving its native architecture and tumor microenvironment so we can measure drug response in real patient tumors rather than simplified models. We work with pharmaceutical and biotech companies, CROs and academic groups to help characterize how therapies perform in human tissue, from early discovery through IND-enabling studies. We have compared our ex vivo data with patient clinical outcomes and presented it at ASCO and AACR, and an NSF SBIR Phase II award supports our work. Our goal is simple: give drug developers human-relevant evidence earlier, so better decisions are made before a therapy reaches the clinic.